Trends and Outcomes of Lung Cancer Surgery in South Korea

Joon Beom Park; Su-Jin Cho; Myung-Il Hahm; Danbee Kang; Seong Yong Park

doi:10.4143/crt.2025.295

Articles

Page Path: HOME > Cancer Res Treat > Volume 58(2); 2026 > Article

Original Article Lung and Thoracic cancer Trends and Outcomes of Lung Cancer Surgery in South Korea: Joon Beom Park¹, Su-Jin Cho², Myung-Il Hahm³, Danbee Kang⁴, Seong Yong Park¹; Cancer Research and Treatment : Official Journal of Korean Cancer Association 2026;58(2):443-453.
DOI: https://doi.org/10.4143/crt.2025.295
Published online: May 27, 2025

¹Department of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

²Health Insurance Review & Assessment Service, Seoul, Korea

³Department of Health Administration and Management, Soonchunhyang University College of Medical Sciences, Asan, Korea

⁴Department of Clinical Research Design and Evaluation, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, Korea

Correspondence: Seong Yong Park, Department of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Korea
Tel: 82-2-3410-1852 E-mail: syparkcs@gmail.com

Co-correspondence: Danbee Kang, Department of Clinical Research Design and Evaluation, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University/Center for Clinical Epidemiology, Samsung Medical Center, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Korea
Tel: 82-2-2148-7197 E-mail: dbee.kang@skku.edu

^*Joon Beom Park and Su-Jin Cho contributed equally to this work.

• Received: March 14, 2025 • Accepted: May 24, 2025

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

3,937 Views
164 Download
2 Web of Science
1 Scopus

prev next

Full Article

Download PDF

Abstract

Purpose
This study analyzed nationwide trends in lung cancer surgery in South Korea over 14 years, focusing on surgical volume, patient demographics, surgical approaches, and outcomes.
Materials and Methods
We performed a retrospective cohort study using nationwide health insurance claims data (124,334 cases) and robotic surgery data (1,740 cases) provided by the manufacturer. Patients who underwent lung cancer surgery between 2010 and 2023 were included. Annual trends were assessed using the annual percentage change (APC), and logistic as well as linear regression models were used to identify predictors of mortality and prolonged hospital stay.
Results
The annual surgical volume increased from 4,557 in 2010 to 14,184 in 2023 (APC, 8.86%; p < 0.001). Video-assisted thoracoscopic surgery (VATS) became the predominant approach, rising from 52.9% to 94.8% (APC, 4.11%; p < 0.001). Sub-lobar resections increased, with wedge resections growing from 9.0% to 18.5% (APC, 5.72%; p < 0.001) and segmentectomies from 3.0% to 17.9% (APC, 14.63%; p < 0.001). The proportion of female patients increased from 32.0% to 44.7% (APC, 2.39%; p < 0.001), while patients aged 70-79 years increased from 26.3% to 32.3% (APC, 1.60%; p < 0.001) and those aged ≥ 80 years from 2.0% to 6.2% (APC, 9.63%; p < 0.001). The median hospital stay decreased from 13 to 7 days (APC, –4.34%; p < 0.001), and 30-day mortality declined from 2.45% to 0.76% (APC, –8.32%; p < 0.001).
Conclusion
Lung cancer surgery in Korea has increased substantially, with a notable shift toward minimally invasive and lung-sparing techniques that have improved outcomes. However, persistent disparities underscore the need for a national surgical registry.
Key words: Lung neoplasms, Thoracic surgery, Minimally invasive surgical procedures, Mortality, Length of stay, Korea

Introduction

Lung cancer remains the leading global health burden, ranking first in both cancer incidence and cancer-related mortality worldwide [1]. In 2021, lung cancer was the third most common cancer in Korea, accounting for 11.4% of all cancers, and it was the leading cause of cancer-related deaths, representing 22.9% of all cancer fatalities [2]. Additionally, the crude incidence rate in Korea continues to rise, largely due to an aging population and the widespread use of low-dose computed tomography (LDCT) [3].

Surgical resection is the treatment of choice for localized lung cancer with curative intent, and the proportion of patients undergoing surgery as primary treatment is expected to continue increasing [4]. However, only 38% of newly diagnosed lung cancer patients in Korea were eligible for surgery as their initial treatment in 2014 [5]. With a 5-year survival rate of 70.6% for localized lung cancer, early surgical intervention is critical [2]. Therefore, the scope of surgery has progressively expanded. The introduction of minimally invasive surgery and the increasing adoption of sub-lobar resections for small (≤ 2 cm), peripherally located tumors have broadened the pool of surgical candidates [6-8]. Furthermore, advancements in chemotherapy and radiotherapy have extended the role of curative surgery to patients with locally advanced lung cancer [9,10].

Although several studies have examined trends and outcomes of lung cancer surgery, most are outdated, limited to single-center data, or cover short-term trends of less than a decade [11-15]. In Korea, the National Health Insurance Service (NHIS) reimburses all lung cancer operations except robotic procedures, enabling comprehensive case identification through claims data [16]. Utilizing nationwide data spanning 14 years (2010-2023), this study offers an updated and representative analysis of lung cancer surgery trends, focusing on surgical volume, patient demographics, surgical methods, and postoperative outcomes.

Materials and Methods

1. Study design and data sources

We conducted a nationwide retrospective cohort study using data from the health insurance claims database, healthcare institution status reports from the Health Insurance Review and Assessment Service (HIRA), and death registration records from the Ministry of the Interior and Safety. Patient demographics and treatment data were obtained from the claims database; healthcare institution characteristics were derived from status reports; and mortality data, including dates of death, were collected from death registration records. Under the universal coverage system, the NHIS covers 97% of the population, while the remaining 3% receive benefits through the Medical Aid Program. HIRA reviews all claims from both NHIS and the Medical Aid Program, ensuring nationwide coverage. As a result, HIRA provides extensive and detailed data on healthcare services—including treatments, medications, procedures, and diagnoses—for nearly 50 million beneficiaries [16]. Since robotic surgery cannot be identified in the claims data, annual numbers were obtained in collaboration with Intuitive Surgical Korea Limited and used solely to analyze trends in lung cancer surgery volume and approaches.

2. Study participants

We identified patients diagnosed with or suspected of having lung cancer who subsequently underwent surgery between January 1, 2010, and December 31, 2023. Patients were initially selected if they had at least one claim for a primary or secondary diagnosis of lung cancer (C34: malignant neoplasm of the lung), abnormal lung imaging findings (R91), or suspected neoplasm (Z031). Among these, patients were classified as lung cancer surgery cases if they met all of the following criteria: (1) at least one lung cancer surgery procedure code (O1401, O1403, O1404, O1405, O1410, O1421, O1422, O1423, O1424, O1431, O1432); (2) at least one general anesthesia code (L1211, L1212); and (3) at least one malignancy pathologic testing code (C5500, C5504, C5505, C5508, C5918, C5919, C5606-C5607).

3. Variable definitions

Demographic variables included sex, age, economic status, and comorbidities. Economic status was categorized by health insurance type—either standard health insurance or Medical Aid, a tax-funded program designed to ensure healthcare access for low-income citizens. Comorbidities during the year preceding the index lung cancer surgery were defined using claims data and International Classification of Diseases, 10th revision (ICD-10) codes, and summarized using the Charlson Comorbidity Index (CCI).

The variable for preoperative treatment was defined by whether patients received radiation or chemotherapy within 180 days prior to surgery-related hospitalization. Radiation therapy was identified based on claims for 25 procedure codes across seven categories, including intensity-modulated radiotherapy, the most commonly used modality for lung cancer treatment. Chemotherapy administration was determined using 32 lung cancer–specific drugs covered under the National Health Insurance (S1 Table). Patients who received both radiation therapy and chemotherapy were classified as having undergone neoadjuvant chemoradiotherapy (NeoCCRTx), those who received chemotherapy alone as having undergone neoadjuvant chemotherapy (NeoCTx), and all others as having undergone upfront surgery.

The surgical approach was categorized as either video-assisted thoracoscopic surgery (VATS) or open surgery. Procedures were classified as VATS if claims for endoscopic procedures (N0031001, N0031002) were present; otherwise, they were categorized as open surgery. Surgical extents were classified as wedge resection (O1401, O1403, O1404, O1405), segmentectomy (O1410), lobectomy (O1421, O1422, O1423, O1424), or pneumonectomy (O1431, O1432) based on 11 procedure codes. If multiple procedures were performed during a single surgery, classification was prioritized in the following order: pneumonectomy > lobectomy > segmentectomy > wedge resection.

Healthcare institution characteristics were categorized by hospital type (tertiary or general hospital), geographic region (metropolitan: Seoul, Incheon, or Gyeonggi), and administrative division (district, city, or county). Finally, surgical outcomes included in-hospital mortality, 30-day mortality, and average length of stay.

4. Statistical analysis

Descriptive statistics were used to assess the distribution of annual surgical cases based on demographic, surgical treatment, and healthcare institution characteristics. Annual trends in surgical volume, patient characteristics, and outcomes were analyzed using annual percentage change (APC), estimated via a log-linear regression model under the assumption of a consistent trend. APC values and their statistical significance are presented in S2 Table. Logistic regression was used to analyze associations between each characteristic and either in-hospital or 30-day mortality, while linear regression identified factors influencing the length of hospital stay. A p-value of < 0.05 was considered statistically significant for all analyses. All analyses were conducted using SAS Enterprise Guide 7.1 (SAS Institute Inc.) and R 4.4.0 (R Foundation for Statistical Computing).

Results

1. Total number of lung cancer operations and surgical approaches

Between 2010 and 2023, a total of 124,334 lung cancer operations were identified using the health insurance claims database, and an additional 1,740 robotic lung cancer operations were estimated by Intuitive Surgical Korea Limited. During this period, the annual number of operations in South Korea increased from 4,557 in 2010 to 14,184 in 2023, representing more than a threefold growth (APC, 8.86%; p < 0.001). Fig. 1A illustrates the trend in the total number of lung cancer operations, including robotic operations.

The number of operations by approach is shown in Fig. 1B. VATS became the predominant surgical approach, increasing from 52.9% of cases in 2010 to 94.8% in 2023 (APC, 4.11%; p < 0.001). Conversely, the proportion of open thoracotomy procedures decreased from 45.6% to 2.1% (APC, –20.75%; p < 0.001). Although robotic surgery represented a relatively small fraction, it accounted for 3.17% of all procedures, with 450 cases in 2023—surpassing the number of open operations for the first time (APC, 11.49%; p < 0.001). However, as detailed patient information on robotic surgery was unavailable, these cases were excluded from further analysis.

2. Patient demographics

The proportion of female patients undergoing surgery increased from 32.0% in 2010 to 44.7% in 2023 (APC, 2.39%; p < 0.001). The percentage of patients aged 70-79 years rose from 26.3% to 32.3% (APC, 1.60%; p < 0.001), and those aged 80 years or older increased from 2.0% to 6.2% (APC, 9.63%; p < 0.001). In contrast, there was no significant change in the proportion of patients aged 60-69 years (APC, 0.30%; p=0.178), whereas the proportions of younger age groups declined (APC for < 40, 40-49, and 50-59 years: –1.94%, –3.51%, and –3.37%, respectively; all p < 0.05). The proportion of patients with CCI scores of 7 or higher increased from 9.0% in 2010 to 17.4% in 2023, indicating a trend toward performing surgery on patients with greater comorbidities (APC, 6.07%; p < 0.001). Health insurance remained the predominant payer, covering 95.7% of operations in 2010 and 95.2% in 2023 (APC, –0.04%; p=0.013), while the proportion of Medical Aid cases increased slightly from 4.3% to 4.8% (APC, 0.91%; p=0.017) (Table 1).

3. Surgical treatment

Lobectomy remained the most common procedure; however, its proportion continuously declined from 82.7% in 2010 to 63.1% in 2023 (APC, –1.91%; p < 0.001). In contrast, sub-lobar resections increased, with wedge resection rising from 9.0% to 18.5% (APC, 5.72%; p < 0.001) and segmentectomy increasing from 3.0% to 17.9% (APC, 14.63%; p < 0.001). Pneumonectomy declined sharply from 5.3% to 0.5% (APC, –15.43%; p < 0.001) (Table 1, Fig. 2A).

Upfront surgery, performed without neoadjuvant treatment, accounted for 94.2% of cases in 2010 and increased to 98.2% in 2023 (APC, 0.30%; p < 0.001). Although the absolute number of operations following neoadjuvant therapy remained stable—averaging 162 procedures annually for NeoCCRTx and 155 for NeoCTx—the proportions of patients receiving NeoCCRTx (declining from 2.2% to 0.8%; APC, –6.10%; p < 0.001) and NeoCTx (declining from 3.5% to 1.1%; APC, –8.64%; p < 0.001) both decreased (Table 1, Fig. 2B).

4. Institutional and regional distribution

The proportion of operations performed at tertiary hospitals increased from 75.9% in 2010 to 81.9% in 2023 (APC, 0.64%; p < 0.001), while that of operations at general hospitals declined from 24.1% to 18.1% (APC, –2.95%; p < 0.001). The proportion of operations in metropolitan areas remained stable, changing from 76.6% to 76.4% (APC, 0.03%; p=0.671). In 2023, when classified by administrative division, district-level institutions accounted for 71.5% of cases, city-level institutions for 23.1%, and county-level institutions for 5.4%, with minimal changes over time (Table 1).

5. Length of hospital stay and operative mortality

The median hospital stay decreased from 13 days in 2010 to 7 days in 2023 (APC, –4.34%; p < 0.001), a trend confirmed by multivariable linear regression analysis. Additionally, linear regression identified several factors associated with prolonged hospitalization, including male sex, older age, Medical Aid status, higher CCI scores (≥ 7), neoadjuvant therapy, open surgery, broader surgical extent, treatment at general hospitals, and care at provincial or city district-level hospitals (Table 2, S3 Table).

In-hospital mortality declined from 1.74% in 2010 to 0.48% in 2023 (APC, –8.26%; p < 0.001), while 30-day mortality decreased from 2.45% to 0.76% (APC, –8.32%; p < 0.001) (Fig. 3). This declining trend was also evident in multivariable logistic regression analysis. Higher mortality rates were observed among male patients, older individuals, Medical Aid beneficiaries, and those with higher CCI scores (≥ 5). Patients undergoing open surgery, more extensive procedures (lobectomy and pneumonectomy versus wedge resection), or neoadjuvant therapy experienced significantly higher mortality, particularly in general hospitals and provincial regions (Table 2, S4 and S5 Tables).

Discussion

In this nationwide cohort study spanning 14 years, we analyzed trends in lung cancer surgery with a focus on patient demographics, surgical methods, and outcomes. Our findings highlight three key trends: (1) an increase in lung cancer operations—especially among women, elderly patients, and those with multiple comorbidities; (2) a shift toward less invasive techniques, including VATS and sub-lobar resections; and (3) improved surgical outcomes characterized by shorter hospital stays and lower mortality rates.

1. Increasing lung cancer incidence and surgical volume

The rise in lung cancer operations corresponds to an increasing crude incidence rate of lung cancer in Korea—from 42.8 to 61.6 per 100,000 between 2010 and 2021. However, the age-standardized incidence rate remained stable (62.9 vs. 59.3 per 100,000), indicating that lung cancer risk within individual age groups has not significantly changed. This suggests that the overall increase is driven by a growing population of older adults, who exhibit a higher incidence than younger individuals [17]. This trend is also seen in our study, with higher proportions of older and high-comorbidity patients undergoing lung cancer surgery.

The proportion of female patients undergoing surgery increased significantly from 32.0% to 43.5% between 2010 and 2021, outpacing the overall increase in female lung cancer diagnoses (from 29.5% to 33.0%) during the same period. A key factor is the higher proportion of localized-stage lung cancer among women, as shown by Surveillance, Epidemiology, and End Results (SEER) staging, which increased from 21.1% in 2010 to 37.3% in 2021 (compared to 18.2% to 24.5% in men) [17]. Since most female lung cancer patients in South Korea are never-smokers, this trend aligns with the global rise in lung cancer among never-smokers (LCINS) [5,13]. Potential risk factors for LCINS include secondhand smoke exposure, cooking fumes, radon, air pollution, occupational hazards, genetic susceptibility, and hormonal replacement therapy, although definitive causal relationships remain unclear [18]. Moreover, adenocarcinoma—the predominant histologic subtype in never-smokers—is often peripherally located and less aggressive, making these patients more likely candidates for surgery [19,20].

While lung cancer incidence in Korea increased 1.5-fold from 21,373 cases in 2010 to 31,616 in 2021, the number of lung cancer operations tripled during the same period (from 4,557 in 2010 to 12,609 in 2021). This suggests that improved early detection and expanding surgical indications have both contributed to the rise in operations.

2. Shift toward less invasive and lung-sparing surgery

Recent trends in Korea reveal a marked transition toward less invasive and lung-preserving surgical strategies for lung cancer. The proportion of patients receiving neoadjuvant therapy has steadily declined, while upfront surgery increased from 94.2% in 2010 to 98.2% in 2023. This shift is likely driven by earlier detection via widespread LDCT screening, as well as a prevailing preference among Korean thoracic surgeons for immediate resection due to concerns over disease progression and surgical complexity following neoadjuvant therapy. Furthermore, the clinical use of neoadjuvant immunotherapy remains limited, as it was only approved in Korea in October 2022 and is not yet widely reimbursed. Nevertheless, the use of neoadjuvant strategies, particularly immunotherapy, is expected to rise as evidence and clinical experience accumulate.

Minimally invasive approaches have become the dominant surgical modality, with VATS accounting for 97.8% of all cases in 2023. VATS is supported by international guidelines for its benefits in reducing postoperative complications, shortening recovery time, and preserving oncologic out-comes [21,22]. Although robotic-assisted thoracic surgery represented only 3.17% of cases in 2023, it surpassed open surgery volume for the first time. Unlike in the United States, where over 60% of lobectomies are now performed robotically according to the Society of Thoracic Surgeons General Thoracic Surgery Database [23], adoption in Korea remains modest due to limited insurance coverage and the earlier widespread implementation of VATS. Nonetheless, increasing familiarity with robotic systems may facilitate future uptake, particularly if evidence emerges supporting superior outcomes in Asian populations [24].

Parallel to the rise in minimally invasive techniques, the use of sub-lobar resections has expanded significantly. In 2023, sub-lobar resections accounted for 36.5% of all procedures, driven by growing evidence—such as from JCOG-0802/WJOG4607L and CALGB 140503—that these approaches offer oncologic equivalence to lobectomy in small peripheral tumors [6,25]. The use of pneumonectomy has declined markedly, often supplanted by lung-sparing techniques like sleeve lobectomy [26]. These collective trends reflect a broader shift toward surgical de-escalation, allowing more elderly and comorbid patients to become surgical candidates and contributing to the overall rise in lung cancer operations in Korea. This evolution in practice parallels global developments and highlights Korea’s alignment with evidence-based, patient-centered surgical care.

3. Improving surgical outcomes and addressing disparities

Surgical outcomes significantly improved from 2010 to 2023. The median hospital stay was reduced from 13 days to 7 days, in-hospital mortality decreased from 1.74% to 0.48%, and 30-day mortality dropped from 2.45% to 0.76%. Despite an increase in high-risk factors such as older age and higher CCI scores, these improvements are likely attributable to a higher proportion of favorable prognostic factors—such as more female patients, upfront operations, minimally invasive approaches, sub-lobar resections, and treatment at tertiary centers—which have collectively enhanced postoperative recovery and reduced mortality.

Disparities persist, with poorer outcomes observed among Medical Aid beneficiaries and patients treated at provincial hospitals, highlighting the need for enhanced perioperative care and social support programs. High-volume tertiary centers were associated with better outcomes, consistent with previous studies demonstrating a volume-outcome relationship in thoracic surgery [27]. Nonetheless, small-volume centers can achieve comparable results with structured surgical training, standardized perioperative protocols, comorbidity optimization, and multidisciplinary decision-making [28].

Currently, no national registry comprehensively tracks lung cancer surgery volume and outcomes in South Korea. In contrast, Japan’s National Clinical Database (NCD) is a nationwide online system that registers surgical patients as part of the Japanese Surgical Board Certification System. The NCD facilitates the collection of data on patient characteristics, operative information, and postoperative events [29]. Establishing a similar registry in South Korea would enable more precise data collection, facilitate policy development, and improve national surgical quality standards.

4. Limitations

This study has several limitations. As a claims-based analysis, it lacks detailed clinical data. First, the absence of precise staging information limits stage-specific mortality analysis. To address this, staging was approximated using neoadjuvant therapy administration, in line with SEER classification. Second, some cases may have involved biopsies or salvage surgery for advanced disease. However, non-surgical biopsy is generally preferred for advanced lung cancer, and the low rate of preoperative therapy suggests that most operations were intended to be curative. Third, robotic surgery data were unavailable in the claims database and were instead estimated separately. Given that robotic operations account for only a very small proportion, their exclusion likely had minimal impact on our findings. Despite these limitations, this study represents the first nationwide, long-term analysis of lung cancer surgery trends in Korea, providing valuable data for future policy and clinical improvements.

Electronic Supplementary Material

Supplementary materials are available at Cancer Research and Treatment website (https://www.e-crt.org).

crt-2025-295_S1_Table.xlsx

crt-2025-295_S2_Table.xlsx

crt-2025-295_S3_Table.xlsx

crt-2025-295_S4_Table.xlsx

crt-2025-295_S5_Table.xlsx

NOTES

Ethical Statement

This study was approved by the Institutional Review Board of Samsung Medical Center (SMC-2024-11-055), with informed consent waived owing to its retrospective design using de-identified data.

Author Contributions

Conceived and designed the analysis: Hahm MI, Park SY.

Collected the data: Cho SJ. Contributed data or analysis tools: Cho SJ, Kang D.

Performed the analysis: Park JB, Cho SJ.

Wrote the paper: Park JB.

Conflict of Interest

Conflict of interest relevant to this article was not reported.

Funding

This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (Ministry of Science and ICT) (No. RS-2025-00553825).

Fig. 1.

Trends in pulmonary resection of lung cancer. Number of lung cancer surgery cases from 2010 to 2023 in Korea. Robotic surgery numbers were estimated in tens. (A) Total cases. (B) By various surgical approaches. VATS, video-assisted thoracoscopic surgery.

Fig. 2.

Trends of pulmonary resection of lung cancer. Number of lung cancer surgery cases from 2010 to 2023 in Korea. (A) Extent of surgical resection excluding robotic surgery. (B) Distribution by preoperative treatment, excluding robotic surgery. CCRTx, concurrent chemoradiotherapy; CTx, chemotherapy.

Fig. 3.

Trends of surgical outcomes. (A) In-hospital and 30-day mortality rates. (B) Hospital stays (day), presented as median (line) and interquartile range (shaded area).

Table 1.

Basic characteristics of patients who underwent pulmonary resection for lung cancer

	Year
	2010	2011	2012	2013	2014	2015	2016
Total No.	4,487	5,347	5,880	6,417	7,182	8,214	9,037
Female sex	1,435 (32.0)	1,834 (34.3)	2,154 (36.6)	2,318 (36.1)	2,590 (37.8)	2,731 (38.0)	3,259 (39.7)
Age (yr)
< 40	86 (1.9)	101 (1.9)	96 (1.6)	102 (1.6)	110 (1.6)	102 (1.4)	136 (1.7)
40-49	330 (7.4)	380 (7.1)	393 (6.7)	395 (6.2)	422 (6.2)	441 (6.1)	470 (5.7)
50-59	1,028 (22.9)	1,337 (25.0)	1,334 (22.7)	1,538 (24.0)	1,625 (23.7)	1,599 (22.3)	1,846 (22.5)
60-69	1,772 (39.5)	2,033 (38.0)	2,233 (38.0)	2,344 (36.5)	2,460 (35.9)	2,641 (36.8)	3,046 (37.1)
70-79	1,180 (26.3)	1,394 (26.1)	1,667 (28.4)	1,867 (29.1)	2,032 (29.7)	2,165 (30.1)	2,433 (29.6)
≥ 80	91 (2.0)	102 (1.9)	157 (2.7)	171 (2.7)	196 (2.9)	234 (3.3)	283 (3.4)
Insurance
Health insurance	4,293 (95.7)	5,106 (95.5)	5,612 (95.4)	6,119 (95.4)	6,558 (95.8)	6,857 (95.5)	7,886 (96.0)
Medical Aid	194 (4.3)	241 (4.5)	268 (4.6)	298 (4.6)	287 (4.2)	325 (4.5)	328 (4.0)
CCI
< 2	1,647 (36.7)	2,018 (37.7)	2,123 (36.1)	2,253 (35.1)	2,320 (33.9)	2,298 (32.0)	2,475 (30.1)
3-4	1,618 (36.1)	2,032 (38.0)	2,317 (39.4)	2,559 (39.9)	2,774 (40.5)	2,943 (41.0)	3,246 (39.5)
5-6	820 (18.3)	884 (16.5)	957 (16.3)	1,085 (16.9)	1,101 (16.1)	1,243 (17.3)	1,583 (19.3)
≥ 7	402 (9.0)	413 (7.7)	483 (8.2)	520 (8.1)	650 (9.5)	698 (9.7)	910 (11.1)
Preoperative Tx.
Upfront	4,228 (94.2)	5,054 (94.5)	5,575 (94.8)	6,096 (95.0)	6,519 (95.2)	6,887 (95.9)	7,894 (96.1)
NeoCTx	159 (3.5)	165 (3.1)	163 (2.8)	167 (2.6)	169 (2.5)	137 (1.9)	131 (1.6)
NeoCCRTx	100 (2.2)	128 (2.4)	142 (2.4)	154 (2.4)	157 (2.3)	158 (2.2)	189 (2.3)
Surgical approach
Open	2,077 (46.3)	2,037 (38.1)	1,958 (33.3)	1,687 (26.3)	1,489 (21.8)	1,242 (17.3)	1,143 (13.9)
VATS	2,410 (53.7)	3,310 (61.9)	3,922 (66.7)	4,730 (73.7)	5,356 (78.2)	5,940 (82.7)	7,071 (86.1)
Surgical extent
Wedge resection	402 (9.0)	491 (9.2)	583 (9.9)	752 (11.7)	790 (11.5)	804 (11.2)	854 (10.4)
Segmentectomy	136 (3.0)	152 (2.8)	229 (3.9)	275 (4.3)	459 (6.7)	514 (7.2)	673 (8.2)
Lobectomy	3,710 (82.7)	4,443 (83.1)	4,820 (82.0)	5,163 (80.5)	5,385 (78.7)	5,638 (78.5)	6,487 (79.0)
Pneumonectomy	239 (5.3)	261 (4.9)	248 (4.2)	227 (3.5)	211 (3.1)	226 (3.1)	200 (2.4)
Hospital type
Tertiary	3,407 (75.9)	3,820 (71.4)	4,414 (75.1)	4,888 (76.2)	5,280 (77.1)	5,714 (79.6)	6,544 (79.7)
General	1,080 (24.1)	1,527 (28.6)	1,466 (24.9)	1,529 (23.8)	1,565 (22.9)	1,468 (20.4)	1,670 (20.3)
Region
Provinces	1,052 (23.4)	1,297 (24.3)	1,576 (26.8)	1,643 (25.6)	1,711 (25.0)	1,751 (24.4)	2,010 (24.5)
Metropolitan	3,435 (76.6)	4,050 (75.7)	4,304 (73.2)	4,774 (74.4)	5,134 (75.0)	5,431 (75.6)	6,204 (75.5)
Administrative division type
District	3,267 (72.8)	3,738 (69.9)	4,195 (71.3)	4,679 (72.9)	5,096 (74.4)	5,193 (72.3)	5,913 (72.0)
City	1,066 (23.8)	1,319 (24.7)	1,305 (22.2)	1,329 (20.7)	1,383 (20.2)	1,568 (21.8)	1,810 (22.0)
County	154 (3.4)	290 (5.4)	380 (6.5)	409 (6.4)	366 (5.3)	421 (5.9)	491 (6.0)
Total No.	9,037	10,050	10,987	10,915	12,399	12,840	13,734
Female sex	3,591 (39.7)	4,214 (41.9)	4,645 (42.3)	4,561 (41.8)	5,392 (43.5)	5,765 (44.9)	6,135 (44.7)
Age (yr)
< 40	120 (1.3)	138 (1.4)	160 (1.5)	149 (1.4)	181 (1.5)	207 (1.6)	183 (1.3)
40-49	528 (5.8)	550 (5.5)	545 (5.0)	533 (4.9)	588 (4.7)	645 (5.0)	628 (4.6)
50-59	1,940 (21.5)	1,964 (19.5)	2,099 (19.1)	1,961 (18.0)	2,139 (17.3)	2,097 (16.3)	2,151 (15.7)
60-69	3,301 (36.5)	3,762 (37.4)	4,238 (38.6)	4,144 (38.0)	4,852 (39.1)	5,007 (39.0)	5,473 (39.9)
70-79	2,773 (30.7)	3,164 (31.5)	3,445 (31.4)	3,588 (32.9)	3,949 (31.8)	4,098 (31.9)	4,442 (32.3)
≥ 80	375 (4.1)	472 (4.7)	500 (4.6)	540 (4.9)	690 (5.6)	786 (6.1)	857 (6.2)
Insurance
Health insurance	8,609 (95.3)	9,573 (95.3)	10,460 (95.2)	10,376 (95.1)	11,791 (95.1)	12,219 (95.2)	13,070 (95.2)
Medical Aid	428 (4.7)	477 (4.7)	527 (4.8)	539 (4.9)	608 (4.9)	621 (4.8)	664 (4.8)
CCI
< 2	2,718 (30.1)	2,701 (26.9)	3,044 (27.7)	3,104 (28.4)	3,747 (30.2)	3,720 (29.0)	3,973 (28.9)
3-4	3,657 (40.5)	4,353 (43.3)	4,445 (40.5)	4,264 (39.1)	4,746 (38.3)	4,719 (36.8)	4,914 (35.8)
5-6	1,615 (17.9)	1,821 (18.1)	2,109 (19.2)	2,059 (18.9)	2,286 (18.4)	2,286 (17.8)	2,464 (17.9)
≥ 7	1,047 (11.6)	1,175 (11.7)	1,389 (12.6)	1,488 (13.6)	1,620 (13.1)	2,115 (16.5)	2,383 (17.4)
Preoperative Tx.
Upfront	8,660 (95.8)	9,701 (96.5)	10,621 (96.7)	10,586 (97.0)	12,063 (97.3)	12,533 (97.6)	13,481 (98.2)
NeoCTx	173 (1.9)	161 (1.6)	162 (1.5)	155 (1.4)	132 (1.1)	154 (1.2)	146 (1.1)
NeoCCRTx	204 (2.3)	188 (1.9)	204 (1.9)	174 (1.6)	204 (1.6)	153 (1.2)	107 (0.8)
Surgical approach
Open	1,030 (11.4)	879 (8.7)	821 (7.5)	636 (5.8)	587 (4.7)	335 (2.6)	291 (2.1)
VATS	8,007 (88.6)	9,171 (91.3)	10,166 (92.5)	10,279 (94.2)	11,812 (95.3)	12,505 (97.4)	13,443 (97.9)
Surgical extent
Wedge resection	1,107 (12.2)	1,393 (13.9)	1,725 (15.7)	1,719 (15.7)	2,073 (16.7)	2,190 (17.1)	2,535 (18.5)
Segmentectomy	722 (8.0)	912 (9.1)	1,094 (10.0)	1,228 (11.3)	1,605 (12.9)	1,965 (15.3)	2,461 (17.9)
Lobectomy	7,010 (77.6)	7,571 (75.3)	7,994 (72.8)	7,835 (71.8)	8,599 (69.4)	8,580 (66.8)	8,663 (63.1)
Pneumonectomy	198 (2.2)	174 (1.7)	174 (1.6)	133 (1.2)	122 (1.0)	105 (0.8)	75 (0.5)
Hospital type
Tertiary	7,175 (79.4)	8,025 (79.9)	8,674 (78.9)	8,732 (80.0)	10,203 (82.3)	10,540 (82.1)	11,254 (81.9)
General	1,862 (20.6)	2,025 (20.1)	2,313 (21.1)	2,183 (20.0)	2,196 (17.7)	2,300 (17.9)	2,480 (18.1)
Region
Provinces	2,204 (24.4)	2,460 (24.5)	2,704 (24.6)	2,797 (25.6)	3,133 (25.3)	3,128 (24.4)	3,237 (23.6)
Metropolitan	6,833 (75.6)	7,590 (75.5)	8,283 (75.4)	8,118 (74.4)	9,266 (74.7)	9,712 (75.6)	10,497 (76.4)
Administrative division type
District	6,495 (71.9)	7,132 (71.0)	7,777 (70.8)	7,704 (70.6)	8,852 (71.4)	9,169 (71.4)	9,818 (71.5)
City	2,001 (22.1)	2,299 (22.9)	2,566 (23.4)	2,553 (23.4)	2,835 (22.9)	2,952 (23.0)	3,179 (23.1)
County	541 (6.0)	619 (6.2)	644 (5.9)	658 (6.0)	712 (5.7)	719 (5.6)	737 (5.4)

Values are presented as number (%). CCI, Charlson comorbidity index; CCRTx, concurrent chemoradiotherapy; CTx, chemotherapy; Tx, treatment; VATS, video-assisted thoracoscopic surgery.

Table 2.

Multivariable analysis for in-hospital mortality, 30-day mortality and hospital stay

Variable	Hospital stay^a)		In-hospital mortality^b)		30-Day mortality^b)
Variable	Coefficient	p-value	OR (95% CI)	p-value	OR (95% CI)	p-value
Year
2010-2012	Reference		Reference		Reference
2013-2016	–1.758	< 0.001	0.76 (0.64-0.91)	0.003	0.75 (0.65-0.87)	< 0.001
2017-2020	–3.044	< 0.001	0.70 (0.59-0.84)	< 0.001	0.64 (0.55-0.74)	< 0.001
2021-2023	–4.317	< 0.001	0.50 (0.41-0.61)	< 0.001	0.49 (0.42-0.58)	< 0.001
Sex
Male	Reference		Reference		Reference
Female	–2.201	< 0.001	0.23 (0.19-0.28)	< 0.001	0.24 (0.21-0.29)	< 0.001
Age (yr)
< 50	Reference		Reference		Reference
50-59	0.450	0.001	1.49 (0.78-2.85)	0.232	1.35 (0.82-2.22)	0.243
60-69	1.348	< 0.001	4.44 (2.43-8.12)	< 0.001	3.66 (2.31-5.82)	< 0.001
70-79	2.571	< 0.001	9.70 (5.32-17.70)	< 0.001	8.23 (5.20-13.03)	< 0.001
≥ 80	3.435	< 0.001	18.02 (9.66-33.60)	< 0.001	15.96 (9.89-25.75)	< 0.001
Insurance
Health insurance	Reference		Reference		Reference
Medical Aid	2.430	< 0.001	1.51 (1.22-1.86)	< 0.001	1.61 (1.35-1.91)	< 0.001
CCI
< 2	Reference		Reference		Reference
3-4	–0.567	< 0.001	1.09 (0.92-1.30)	0.334	1.12 (0.97-1.29)	0.139
5-6	–0.034	0.730	1.46 (1.21-1.76)	0.001	1.43 (1.22-1.67)	< 0.001
≥ 7	0.834	< 0.001	1.89 (1.56-2.28)	< 0.001	1.95 (1.67-2.29)	< 0.001
Preoperative Tx.
Upfront	Reference		Reference		Reference
NeoCTx	0.812	< 0.001	1.55 (1.14-2.11)	0.005	1.61 (1.25-2.09)	< 0.001
NeoCCRTx	1.281	< 0.001	2.21 (1.67-2.93)	< 0.001	2.24 (1.85-2.97)	< 0.001
Surgical approach
Open	Reference		Reference		Reference
VATS	–3.251	< 0.001	0.61 (0.53-0.70)	< 0.001	0.56 (0.50-0.63)	< 0.001
Surgical extent
Wedge resection	Reference		Reference		Reference
Segmentectomy	1.017	< 0.001	1.10 (0.75-1.62)	0.614	0.87 (0.65-1.15)	0.324
Lobectomy	2.750	< 0.001	2.37 (1.85-3.03)	< 0.001	1.56 (1.31-1.86)	< 0.001
Pneumonectomy	7.070	< 0.001	8.31 (6.10-11.31)	< 0.001	4.82 (3.79-6.13)	< 0.001
Hospital type
Tertiary	Reference		Reference		Reference
General	3.494	< 0.001	1.68 (1.48-1.91)	< 0.001	1.62 (1.46-1.81)	< 0.001
Region
Provinces	Reference		Reference		Reference
Metropolitan	–2.420	< 0.001	0.65 (0.57-0.74)	< 0.001	0.66 (0.59-0.73)	< 0.001
Administrative division type
District	Reference		Reference		Reference
City	0.503	< 0.001	0.96 (0.83-1.10)	0.535	0.95 (0.85-1.07)	0.416
County	0.186	0.227	0.87 (0.68-1.11)	0.257	0.92 (0.75-1.12)	0.396

CCI, Charlson comorbidity index; CCRTx, concurrent chemoradiotherapy; CI, confidence interval; CTx, chemotherapy; OR, odds ratio; Tx, treatment; VATS, video-assisted thoracoscopic surgery.

^a) Multivariable linear regression,

^b) Multivariable logistic regression.

REFERENCES

1. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229–63. Article PubMed
2. Park EH, Jung KW, Park NJ, Kang MJ, Yun EH, Kim HJ, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2021. Cancer Res Treat. 2024;56:357–71. Article PubMed PMC PDF
3. Bonney A, Malouf R, Marchal C, Manners D, Fong KM, Marshall HM, et al. Impact of low-dose computed tomography (LDCT) screening on lung cancer-related mortality. Cochrane Database Syst Rev. 2022;8:CD013829.Article PubMed PMC
4. Jeon DS, Kim HC, Kim SH, Kim TJ, Kim HK, Moon MH, et al. Five-year overall survival and prognostic factors in patients with lung cancer: results from the Korean Association of Lung Cancer Registry (KALC-R) 2015. Cancer Res Treat. 2023;55:103–11. Article PubMed PDF
5. Choi CM, Kim HC, Jung CY, Cho DG, Jeon JH, Lee JE, et al. Report of the Korean Association of Lung Cancer Registry (KALC-R), 2014. Cancer Res Treat. 2019;51:1400–10. Article PubMed PMC PDF
6. Saji H, Okada M, Tsuboi M, Nakajima R, Suzuki K, Aokage K, et al. Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial. Lancet. 2022;399:1607–17. Article PubMed
7. Vannucci F, Gonzalez-Rivas D. Is VATS lobectomy standard of care for operable non-small cell lung cancer? Lung Cancer. 2016;100:114–9. Article PubMed
8. Kanzaki M. Current status of robot-assisted thoracoscopic surgery for lung cancer. Surg Today. 2019;49:795–802. Article PubMed PDF
9. Sher DJ, Fidler MJ, Liptay MJ, Koshy M. Comparative effectiveness of neoadjuvant chemoradiotherapy versus chemotherapy alone followed by surgery for patients with stage IIIA non-small cell lung cancer. Lung Cancer. 2015;88:267–74. Article PubMed
10. Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022;386:1973–85. PubMed PMC
11. Kim D, Lee JW. Current status of lung cancer and surgery based on studies using a nationwide database. J Chest Surg. 2022;55:1–9. Article PubMed PMC
12. Kim D, Kang GW, Jang H, Cho JY, Yang B, Yang HC, et al. Trend of lung cancer surgery, hospital selection, and survival between 2005 and 2016 in South Korea. Thorac Cancer. 2022;13:210–8. Article PubMed PDF
13. Yun JK, Lee HP, Lee GD, Kim HR, Kim YH, Kim DK, et al. Recent trends in demographics, surgery, and prognosis of patients with surgically resected lung cancer in a single institution from Korea. J Korean Med Sci. 2019;34:e291Article PubMed PMC PDF
14. Kim D, Kim SY, Suh B, Park JH. Trend analysis for the choice and cost of lung cancer treatment in South Korea, 2003-2013. Cancer Res Treat. 2018;50:757–67. Article PubMed PDF
15. Park S, Park IK, Kim ER, Hwang Y, Lee HJ, Kang CH, et al. Current trends of lung cancer surgery and demographic and social factors related to changes in the trends of lung cancer surgery: an analysis of the national database from 2010 to 2014. Cancer Res Treat. 2017;49:330–7. Article PubMed PDF
16. Kim JA, Yoon S, Kim LY, Kim DS. Towards actualizing the value potential of Korea Health Insurance Review and Assessment (HIRA) data as a resource for health research: strengths, limitations, applications, and strategies for optimal use of HIRA data. J Korean Med Sci. 2017;32:718–28. Article PubMed PMC PDF
17. Ministry of Health and Welfare; Korea Central Cancer Registry. Annual report of cancer statistics in Korea (2021 cancer incidence data). Ministry of Health and Welfare, Korea Central Cancer Registry; 2023.
18. Kerpel-Fronius A, Tammemagi M, Cavic M, Henschke C, Jiang L, Kazerooni E, et al. Screening for lung cancer in individuals who never smoked: an international association for the study of lung cancer early detection and screening committee report. J Thorac Oncol. 2022;17:56–66. Article PubMed
19. Rudin CM, Avila-Tang E, Harris CC, Herman JG, Hirsch FR, Pao W, et al. Lung cancer in never smokers: molecular profiles and therapeutic implications. Clin Cancer Res. 2009;15:5646–61. Article PubMed PMC PDF
20. Wang BY, Huang JY, Chen HC, Lin CH, Lin SH, Hung WH, et al. The comparison between adenocarcinoma and squamous cell carcinoma in lung cancer patients. J Cancer Res Clin Oncol. 2020;146:43–52. Article PubMed PDF
21. Howington JA, Blum MG, Chang AC, Balekian AA, Murthy SC. Treatment of stage I and II non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143:e278S–e313S. Article PubMed
22. Expert Consensus Panel; Kidane B, Bott M, Spicer J, Backhus L, Chaft J, et al. The American Association for Thoracic Surgery (AATS) 2023 expert consensus document: staging and multidisciplinary management of patients with early-stage non-small cell lung cancer. J Thorac Cardiovasc Surg. 2023;166:637–54. Article PubMed
23. Towe CW, Kuo EY, Feczko A, Kidane B, Khullar OV, Seder CW, et al. The Society of Thoracic Surgeons general thoracic surgery database: 2024 update on outcomes and research. Ann Thorac Surg. 2025;119:733–43. Article PubMed
24. Huang S, Huang X, Huang Z, Luo R, Liang W. Comparison of robot-assisted thoracic surgery versus video-assisted thoracic surgery in the treatment of lung cancer: a systematic review and meta-analysis of prospective studies. Front Oncol. 2023;13:1271709.Article PubMed PMC
25. Altorki N, Wang X, Kozono D, Watt C, Landrenau R, Wigle D, et al. Lobar or sublobar resection for peripheral stage ia non-small-cell lung cancer. N Engl J Med. 2023;388:489–98. Article PubMed PMC
26. Chen J, Soultanis KM, Sun F, Gonzalez-Rivas D, Duan L, Wu L, et al. Outcomes of sleeve lobectomy versus pneumonectomy: a propensity score-matched study. J Thorac Cardiovasc Surg. 2021;162:1619–28. Article PubMed
27. Kim BR, Sohn JY, Jang EJ, Jo J, Lee H, Ryu HG. Hospital case-volume and mortality after lung cancer surgery: a population-based retrospective cohort study. Lung Cancer. 2022;169:61–6. Article PubMed
28. von Itzstein MS, Lu R, Kernstine KH, Halm EA, Wang S, Xie Y, et al. Closing the gap: contribution of surgical best practices to outcome differences between high- and low-volume centers for lung cancer resection. Cancer Med. 2020;9:4137–47. Article PubMed PMC PDF
29. Ikeda N, Endo S, Fukuchi E, Nakajima J, Yokoi K, Chida M, et al. Current status of surgery for clinical stage ia lung cancer in japan: analysis of the national clinical database. Surg Today. 2020;50:1644–51. Article PubMed PMC PDF

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Trends and Outcomes of Lung Cancer Surgery in South Korea

Cancer Res Treat. 2026;58(2):443-453. Published online May 27, 2025

DOI: https://doi.org/10.4143/crt.2025.295

XML Download

Abstract
Introduction
Materials and Methods
Results
Discussion
Electronic Supplementary Material
NOTES
REFERENCES

Data Resource Profile: The Cancer Public Library Database in South Korea

Trends and Outcomes of Lung Cancer Surgery in South Korea

Fig. 1. Trends in pulmonary resection of lung cancer. Number of lung cancer surgery cases from 2010 to 2023 in Korea. Robotic surgery numbers were estimated in tens. (A) Total cases. (B) By various surgical approaches. VATS, video-assisted thoracoscopic surgery.

Fig. 2. Trends of pulmonary resection of lung cancer. Number of lung cancer surgery cases from 2010 to 2023 in Korea. (A) Extent of surgical resection excluding robotic surgery. (B) Distribution by preoperative treatment, excluding robotic surgery. CCRTx, concurrent chemoradiotherapy; CTx, chemotherapy.

Fig. 3. Trends of surgical outcomes. (A) In-hospital and 30-day mortality rates. (B) Hospital stays (day), presented as median (line) and interquartile range (shaded area).

Fig. 1.

Fig. 2.

Fig. 3.

Trends and Outcomes of Lung Cancer Surgery in South Korea

	Year
	2010	2011	2012	2013	2014	2015	2016
Total No.	4,487	5,347	5,880	6,417	7,182	8,214	9,037
Female sex	1,435 (32.0)	1,834 (34.3)	2,154 (36.6)	2,318 (36.1)	2,590 (37.8)	2,731 (38.0)	3,259 (39.7)
Age (yr)
< 40	86 (1.9)	101 (1.9)	96 (1.6)	102 (1.6)	110 (1.6)	102 (1.4)	136 (1.7)
40-49	330 (7.4)	380 (7.1)	393 (6.7)	395 (6.2)	422 (6.2)	441 (6.1)	470 (5.7)
50-59	1,028 (22.9)	1,337 (25.0)	1,334 (22.7)	1,538 (24.0)	1,625 (23.7)	1,599 (22.3)	1,846 (22.5)
60-69	1,772 (39.5)	2,033 (38.0)	2,233 (38.0)	2,344 (36.5)	2,460 (35.9)	2,641 (36.8)	3,046 (37.1)
70-79	1,180 (26.3)	1,394 (26.1)	1,667 (28.4)	1,867 (29.1)	2,032 (29.7)	2,165 (30.1)	2,433 (29.6)
≥ 80	91 (2.0)	102 (1.9)	157 (2.7)	171 (2.7)	196 (2.9)	234 (3.3)	283 (3.4)
Insurance
Health insurance	4,293 (95.7)	5,106 (95.5)	5,612 (95.4)	6,119 (95.4)	6,558 (95.8)	6,857 (95.5)	7,886 (96.0)
Medical Aid	194 (4.3)	241 (4.5)	268 (4.6)	298 (4.6)	287 (4.2)	325 (4.5)	328 (4.0)
CCI
< 2	1,647 (36.7)	2,018 (37.7)	2,123 (36.1)	2,253 (35.1)	2,320 (33.9)	2,298 (32.0)	2,475 (30.1)
3-4	1,618 (36.1)	2,032 (38.0)	2,317 (39.4)	2,559 (39.9)	2,774 (40.5)	2,943 (41.0)	3,246 (39.5)
5-6	820 (18.3)	884 (16.5)	957 (16.3)	1,085 (16.9)	1,101 (16.1)	1,243 (17.3)	1,583 (19.3)
≥ 7	402 (9.0)	413 (7.7)	483 (8.2)	520 (8.1)	650 (9.5)	698 (9.7)	910 (11.1)
Preoperative Tx.
Upfront	4,228 (94.2)	5,054 (94.5)	5,575 (94.8)	6,096 (95.0)	6,519 (95.2)	6,887 (95.9)	7,894 (96.1)
NeoCTx	159 (3.5)	165 (3.1)	163 (2.8)	167 (2.6)	169 (2.5)	137 (1.9)	131 (1.6)
NeoCCRTx	100 (2.2)	128 (2.4)	142 (2.4)	154 (2.4)	157 (2.3)	158 (2.2)	189 (2.3)
Surgical approach
Open	2,077 (46.3)	2,037 (38.1)	1,958 (33.3)	1,687 (26.3)	1,489 (21.8)	1,242 (17.3)	1,143 (13.9)
VATS	2,410 (53.7)	3,310 (61.9)	3,922 (66.7)	4,730 (73.7)	5,356 (78.2)	5,940 (82.7)	7,071 (86.1)
Surgical extent
Wedge resection	402 (9.0)	491 (9.2)	583 (9.9)	752 (11.7)	790 (11.5)	804 (11.2)	854 (10.4)
Segmentectomy	136 (3.0)	152 (2.8)	229 (3.9)	275 (4.3)	459 (6.7)	514 (7.2)	673 (8.2)
Lobectomy	3,710 (82.7)	4,443 (83.1)	4,820 (82.0)	5,163 (80.5)	5,385 (78.7)	5,638 (78.5)	6,487 (79.0)
Pneumonectomy	239 (5.3)	261 (4.9)	248 (4.2)	227 (3.5)	211 (3.1)	226 (3.1)	200 (2.4)
Hospital type
Tertiary	3,407 (75.9)	3,820 (71.4)	4,414 (75.1)	4,888 (76.2)	5,280 (77.1)	5,714 (79.6)	6,544 (79.7)
General	1,080 (24.1)	1,527 (28.6)	1,466 (24.9)	1,529 (23.8)	1,565 (22.9)	1,468 (20.4)	1,670 (20.3)
Region
Provinces	1,052 (23.4)	1,297 (24.3)	1,576 (26.8)	1,643 (25.6)	1,711 (25.0)	1,751 (24.4)	2,010 (24.5)
Metropolitan	3,435 (76.6)	4,050 (75.7)	4,304 (73.2)	4,774 (74.4)	5,134 (75.0)	5,431 (75.6)	6,204 (75.5)
Administrative division type
District	3,267 (72.8)	3,738 (69.9)	4,195 (71.3)	4,679 (72.9)	5,096 (74.4)	5,193 (72.3)	5,913 (72.0)
City	1,066 (23.8)	1,319 (24.7)	1,305 (22.2)	1,329 (20.7)	1,383 (20.2)	1,568 (21.8)	1,810 (22.0)
County	154 (3.4)	290 (5.4)	380 (6.5)	409 (6.4)	366 (5.3)	421 (5.9)	491 (6.0)
Total No.	9,037	10,050	10,987	10,915	12,399	12,840	13,734
Female sex	3,591 (39.7)	4,214 (41.9)	4,645 (42.3)	4,561 (41.8)	5,392 (43.5)	5,765 (44.9)	6,135 (44.7)
Age (yr)
< 40	120 (1.3)	138 (1.4)	160 (1.5)	149 (1.4)	181 (1.5)	207 (1.6)	183 (1.3)
40-49	528 (5.8)	550 (5.5)	545 (5.0)	533 (4.9)	588 (4.7)	645 (5.0)	628 (4.6)
50-59	1,940 (21.5)	1,964 (19.5)	2,099 (19.1)	1,961 (18.0)	2,139 (17.3)	2,097 (16.3)	2,151 (15.7)
60-69	3,301 (36.5)	3,762 (37.4)	4,238 (38.6)	4,144 (38.0)	4,852 (39.1)	5,007 (39.0)	5,473 (39.9)
70-79	2,773 (30.7)	3,164 (31.5)	3,445 (31.4)	3,588 (32.9)	3,949 (31.8)	4,098 (31.9)	4,442 (32.3)
≥ 80	375 (4.1)	472 (4.7)	500 (4.6)	540 (4.9)	690 (5.6)	786 (6.1)	857 (6.2)
Insurance
Health insurance	8,609 (95.3)	9,573 (95.3)	10,460 (95.2)	10,376 (95.1)	11,791 (95.1)	12,219 (95.2)	13,070 (95.2)
Medical Aid	428 (4.7)	477 (4.7)	527 (4.8)	539 (4.9)	608 (4.9)	621 (4.8)	664 (4.8)
CCI
< 2	2,718 (30.1)	2,701 (26.9)	3,044 (27.7)	3,104 (28.4)	3,747 (30.2)	3,720 (29.0)	3,973 (28.9)
3-4	3,657 (40.5)	4,353 (43.3)	4,445 (40.5)	4,264 (39.1)	4,746 (38.3)	4,719 (36.8)	4,914 (35.8)
5-6	1,615 (17.9)	1,821 (18.1)	2,109 (19.2)	2,059 (18.9)	2,286 (18.4)	2,286 (17.8)	2,464 (17.9)
≥ 7	1,047 (11.6)	1,175 (11.7)	1,389 (12.6)	1,488 (13.6)	1,620 (13.1)	2,115 (16.5)	2,383 (17.4)
Preoperative Tx.
Upfront	8,660 (95.8)	9,701 (96.5)	10,621 (96.7)	10,586 (97.0)	12,063 (97.3)	12,533 (97.6)	13,481 (98.2)
NeoCTx	173 (1.9)	161 (1.6)	162 (1.5)	155 (1.4)	132 (1.1)	154 (1.2)	146 (1.1)
NeoCCRTx	204 (2.3)	188 (1.9)	204 (1.9)	174 (1.6)	204 (1.6)	153 (1.2)	107 (0.8)
Surgical approach
Open	1,030 (11.4)	879 (8.7)	821 (7.5)	636 (5.8)	587 (4.7)	335 (2.6)	291 (2.1)
VATS	8,007 (88.6)	9,171 (91.3)	10,166 (92.5)	10,279 (94.2)	11,812 (95.3)	12,505 (97.4)	13,443 (97.9)
Surgical extent
Wedge resection	1,107 (12.2)	1,393 (13.9)	1,725 (15.7)	1,719 (15.7)	2,073 (16.7)	2,190 (17.1)	2,535 (18.5)
Segmentectomy	722 (8.0)	912 (9.1)	1,094 (10.0)	1,228 (11.3)	1,605 (12.9)	1,965 (15.3)	2,461 (17.9)
Lobectomy	7,010 (77.6)	7,571 (75.3)	7,994 (72.8)	7,835 (71.8)	8,599 (69.4)	8,580 (66.8)	8,663 (63.1)
Pneumonectomy	198 (2.2)	174 (1.7)	174 (1.6)	133 (1.2)	122 (1.0)	105 (0.8)	75 (0.5)
Hospital type
Tertiary	7,175 (79.4)	8,025 (79.9)	8,674 (78.9)	8,732 (80.0)	10,203 (82.3)	10,540 (82.1)	11,254 (81.9)
General	1,862 (20.6)	2,025 (20.1)	2,313 (21.1)	2,183 (20.0)	2,196 (17.7)	2,300 (17.9)	2,480 (18.1)
Region
Provinces	2,204 (24.4)	2,460 (24.5)	2,704 (24.6)	2,797 (25.6)	3,133 (25.3)	3,128 (24.4)	3,237 (23.6)
Metropolitan	6,833 (75.6)	7,590 (75.5)	8,283 (75.4)	8,118 (74.4)	9,266 (74.7)	9,712 (75.6)	10,497 (76.4)
Administrative division type
District	6,495 (71.9)	7,132 (71.0)	7,777 (70.8)	7,704 (70.6)	8,852 (71.4)	9,169 (71.4)	9,818 (71.5)
City	2,001 (22.1)	2,299 (22.9)	2,566 (23.4)	2,553 (23.4)	2,835 (22.9)	2,952 (23.0)	3,179 (23.1)
County	541 (6.0)	619 (6.2)	644 (5.9)	658 (6.0)	712 (5.7)	719 (5.6)	737 (5.4)

Variable	Hospital stay^a)		In-hospital mortality^b)		30-Day mortality^b)
Variable	Coefficient	p-value	OR (95% CI)	p-value	OR (95% CI)	p-value
Year
2010-2012	Reference		Reference		Reference
2013-2016	–1.758	< 0.001	0.76 (0.64-0.91)	0.003	0.75 (0.65-0.87)	< 0.001
2017-2020	–3.044	< 0.001	0.70 (0.59-0.84)	< 0.001	0.64 (0.55-0.74)	< 0.001
2021-2023	–4.317	< 0.001	0.50 (0.41-0.61)	< 0.001	0.49 (0.42-0.58)	< 0.001
Sex
Male	Reference		Reference		Reference
Female	–2.201	< 0.001	0.23 (0.19-0.28)	< 0.001	0.24 (0.21-0.29)	< 0.001
Age (yr)
< 50	Reference		Reference		Reference
50-59	0.450	0.001	1.49 (0.78-2.85)	0.232	1.35 (0.82-2.22)	0.243
60-69	1.348	< 0.001	4.44 (2.43-8.12)	< 0.001	3.66 (2.31-5.82)	< 0.001
70-79	2.571	< 0.001	9.70 (5.32-17.70)	< 0.001	8.23 (5.20-13.03)	< 0.001
≥ 80	3.435	< 0.001	18.02 (9.66-33.60)	< 0.001	15.96 (9.89-25.75)	< 0.001
Insurance
Health insurance	Reference		Reference		Reference
Medical Aid	2.430	< 0.001	1.51 (1.22-1.86)	< 0.001	1.61 (1.35-1.91)	< 0.001
CCI
< 2	Reference		Reference		Reference
3-4	–0.567	< 0.001	1.09 (0.92-1.30)	0.334	1.12 (0.97-1.29)	0.139
5-6	–0.034	0.730	1.46 (1.21-1.76)	0.001	1.43 (1.22-1.67)	< 0.001
≥ 7	0.834	< 0.001	1.89 (1.56-2.28)	< 0.001	1.95 (1.67-2.29)	< 0.001
Preoperative Tx.
Upfront	Reference		Reference		Reference
NeoCTx	0.812	< 0.001	1.55 (1.14-2.11)	0.005	1.61 (1.25-2.09)	< 0.001
NeoCCRTx	1.281	< 0.001	2.21 (1.67-2.93)	< 0.001	2.24 (1.85-2.97)	< 0.001
Surgical approach
Open	Reference		Reference		Reference
VATS	–3.251	< 0.001	0.61 (0.53-0.70)	< 0.001	0.56 (0.50-0.63)	< 0.001
Surgical extent
Wedge resection	Reference		Reference		Reference
Segmentectomy	1.017	< 0.001	1.10 (0.75-1.62)	0.614	0.87 (0.65-1.15)	0.324
Lobectomy	2.750	< 0.001	2.37 (1.85-3.03)	< 0.001	1.56 (1.31-1.86)	< 0.001
Pneumonectomy	7.070	< 0.001	8.31 (6.10-11.31)	< 0.001	4.82 (3.79-6.13)	< 0.001
Hospital type
Tertiary	Reference		Reference		Reference
General	3.494	< 0.001	1.68 (1.48-1.91)	< 0.001	1.62 (1.46-1.81)	< 0.001
Region
Provinces	Reference		Reference		Reference
Metropolitan	–2.420	< 0.001	0.65 (0.57-0.74)	< 0.001	0.66 (0.59-0.73)	< 0.001
Administrative division type
District	Reference		Reference		Reference
City	0.503	< 0.001	0.96 (0.83-1.10)	0.535	0.95 (0.85-1.07)	0.416
County	0.186	0.227	0.87 (0.68-1.11)	0.257	0.92 (0.75-1.12)	0.396

Table 1. Basic characteristics of patients who underwent pulmonary resection for lung cancer

Values are presented as number (%). CCI, Charlson comorbidity index; CCRTx, concurrent chemoradiotherapy; CTx, chemotherapy; Tx, treatment; VATS, video-assisted thoracoscopic surgery.

Table 2. Multivariable analysis for in-hospital mortality, 30-day mortality and hospital stay

CCI, Charlson comorbidity index; CCRTx, concurrent chemoradiotherapy; CI, confidence interval; CTx, chemotherapy; OR, odds ratio; Tx, treatment; VATS, video-assisted thoracoscopic surgery.

Multivariable linear regression,

Multivariable logistic regression.